332 related articles for article (PubMed ID: 23129563)
1. Proteome analysis of body fluids for amyotrophic lateral sclerosis biomarker discovery.
Krüger T; Lautenschläger J; Grosskreutz J; Rhode H
Proteomics Clin Appl; 2013 Jan; 7(1-2):123-35. PubMed ID: 23129563
[TBL] [Abstract][Full Text] [Related]
2. Clinical perspectives of high-resolution mass spectrometry-based proteomics in neuroscience: exemplified in amyotrophic lateral sclerosis biomarker discovery research.
Ekegren T; Hanrieder J; Bergquist J
J Mass Spectrom; 2008 May; 43(5):559-71. PubMed ID: 18416436
[TBL] [Abstract][Full Text] [Related]
3. Protein biomarkers for amyotrophic lateral sclerosis.
Ryberg H; Bowser R
Expert Rev Proteomics; 2008 Apr; 5(2):249-62. PubMed ID: 18466055
[TBL] [Abstract][Full Text] [Related]
4. Multi-Omics for Biomarker Discovery and Target Validation in Biofluids for Amyotrophic Lateral Sclerosis Diagnosis.
Mitropoulos K; Katsila T; Patrinos GP; Pampalakis G
OMICS; 2018 Jan; 22(1):52-64. PubMed ID: 29356625
[TBL] [Abstract][Full Text] [Related]
5. Label-Free LC-MS/MS Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and Candidate Biomarkers for Amyotrophic Lateral Sclerosis.
Collins MA; An J; Hood BL; Conrads TP; Bowser RP
J Proteome Res; 2015 Nov; 14(11):4486-501. PubMed ID: 26401960
[TBL] [Abstract][Full Text] [Related]
6. Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease.
Kolarcik C; Bowser R
Mol Diagn Ther; 2006; 10(5):281-92. PubMed ID: 17022691
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers for amyotrophic lateral sclerosis.
Bowser R; Cudkowicz M; Kaddurah-Daouk R
Expert Rev Mol Diagn; 2006 May; 6(3):387-98. PubMed ID: 16706741
[TBL] [Abstract][Full Text] [Related]
8. Proteomic studies in the discovery of cerebrospinal fluid biomarkers for amyotrophic lateral sclerosis.
Barschke P; Oeckl P; Steinacker P; Ludolph A; Otto M
Expert Rev Proteomics; 2017 Sep; 14(9):769-777. PubMed ID: 28799854
[TBL] [Abstract][Full Text] [Related]
9. Proteome analysis reveals candidate markers of disease progression in amyotrophic lateral sclerosis (ALS).
Brettschneider J; Lehmensiek V; Mogel H; Pfeifle M; Dorst J; Hendrich C; Ludolph AC; Tumani H
Neurosci Lett; 2010 Jan; 468(1):23-7. PubMed ID: 19853641
[TBL] [Abstract][Full Text] [Related]
10. Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future.
Good DM; Thongboonkerd V; Novak J; Bascands JL; Schanstra JP; Coon JJ; Dominiczak A; Mischak H
J Proteome Res; 2007 Dec; 6(12):4549-55. PubMed ID: 17970587
[TBL] [Abstract][Full Text] [Related]
11. Amyotrophic lateral sclerosis--the tools of the trait.
Lederer CW; Santama N
Biotechnol J; 2007 May; 2(5):608-21. PubMed ID: 17345579
[TBL] [Abstract][Full Text] [Related]
12. Are Circulating Cytokines Reliable Biomarkers for Amyotrophic Lateral Sclerosis?
Moreno-Martinez L; Calvo AC; Muñoz MJ; Osta R
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31195629
[TBL] [Abstract][Full Text] [Related]
13. Identification of potential CSF biomarkers in ALS.
Pasinetti GM; Ungar LH; Lange DJ; Yemul S; Deng H; Yuan X; Brown RH; Cudkowicz ME; Newhall K; Peskind E; Marcus S; Ho L
Neurology; 2006 Apr; 66(8):1218-22. PubMed ID: 16481598
[TBL] [Abstract][Full Text] [Related]
14. CSF glial markers correlate with survival in amyotrophic lateral sclerosis.
Süssmuth SD; Sperfeld AD; Hinz A; Brettschneider J; Endruhn S; Ludolph AC; Tumani H
Neurology; 2010 Mar; 74(12):982-7. PubMed ID: 20308682
[TBL] [Abstract][Full Text] [Related]
15. Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS.
Gordon PH; Cheng B; Katz IB; Mitsumoto H; Rowland LP
Neurology; 2009 Jun; 72(22):1948-52. PubMed ID: 19487653
[TBL] [Abstract][Full Text] [Related]
16. Role of proteomics in the discovery of autism biomarkers.
Al-Ayadhi L; Halepoto DM
J Coll Physicians Surg Pak; 2013 Feb; 23(2):137-43. PubMed ID: 23374519
[TBL] [Abstract][Full Text] [Related]
17. [Differential diagnosis and atypical subsets of amyotrophic lateral sclerosis].
Pradat PF; Bruneteau G
Rev Neurol (Paris); 2006 Jun; 162 Spec No 2():4S81-4S90. PubMed ID: 17128093
[TBL] [Abstract][Full Text] [Related]
18. Alterations in muscle proteome of patients diagnosed with amyotrophic lateral sclerosis.
Elf K; Shevchenko G; Nygren I; Larsson L; Bergquist J; Askmark H; Artemenko K
J Proteomics; 2014 Aug; 108():55-64. PubMed ID: 24846852
[TBL] [Abstract][Full Text] [Related]
19. Proteomic analysis of muscle affected by motor neuron degeneration: the wobbler mouse model of amyotrophic lateral sclerosis.
Staunton L; Jockusch H; Ohlendieck K
Biochem Biophys Res Commun; 2011 Mar; 406(4):595-600. PubMed ID: 21354103
[TBL] [Abstract][Full Text] [Related]
20. Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism.
Cervetto C; Frattaroli D; Maura G; Marcoli M
Toxicology; 2013 Sep; 311(1-2):69-77. PubMed ID: 23583883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
